Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Gmax Starts China Phase I Trial of 2nd Gen Obesity Therapy

publication date: Nov 11, 2021

Gmax Biopharm, a novel Hangzhou antibody company focused on GPCRs, has begun a China Phase I trial of its obesity therapy. GMA106 is Gmax's second-gen mAb therapy aimed at obesity/T2DM/NASH. It combines Gmax's GPCR mAb with its M-Body technology, which aims at two different targets for better efficacy. In this case the M-Body pairs an anti-GIPR antibody fused with a GLP-1 peptide. Patients in the Phase I trial will be given a single dose of GMA106. The trial will be structured as a placebo controlled, double blind, randomized, dose escalating study. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital